课题基金 / 基金详情

IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES

IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
风湿性疾病的免疫调节机制
批准号:
3151971
负责人:
DAVID A HORWITZ
金额:
$14.76万
依托单位国家:
美国
项目类别:
财政年份:
1980
资助国家:
美国
项目状态:
已结题
起止时间:
1980-09-01 至 1986-06-30

项目摘要

项目成果

DAVID A HORWITZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The long-term objective of this proposal is to develop a greater understanding of the cellular components which mediate and regulate the human immune response. We plan to identify, characterize and look for abnormalities of newly described subsets of mononuclear cells found in the blood and tissues of patients with rheumatic diseases. We will continue to study "L" cells, a presumptive subset of non-T, non-B cells with high avidity Fc receptors for IgC. The precise relationship of L cells with other mononuclear cells will be investigated by characterizing cell surface antigens on L cells and other mononuclear cells with monoclonal antibodies produced by hybridomas. Flow cytofluorography will be utilized to accomplish this task. Secondly, specific cell-types will be separated on the basis of cell surface markers by cell-sorting and the functional properties of purified cells will be compared using in vitro techniques. We will investigate L cells-T cells interactions in the regulation of B cell function. Thirdly, L cells are excellent mediators of spontaneous or natural killer antibody-dependent cellular cytotoxicity. A comparison of the cytotoxic effects of L cells with other cell types will be continued. Finally, we plan to learn the significance of a cellular cytotoxicity defect we have recently described in rheumatoid arthritis. Studies will be conducted to define the effector cells and regulatory cells involved in this defect, to learn whether this defect may be an important pathogenetic factor in rheumatoid arthritis and to investigate possible means of correcting this defect. It is likely that a better understanding of regulatory abnormalities in patients with rheumatic diseases will lead to new and safer approaches to control these disorders.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 1986
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Bakke,AC, Gray,JD, Abo,W, QuismorioJr,FP, Lash,A, Cooper,SM, Horwitz,DA]
通讯作者: Horwitz,DA
DOI: --
发表时间: 1987
期刊: Clinical and experimental immunology
影响因子: 4.6
作者: [Gray,JD, Lash,A, Bakke,AC, Kitridou,RC, Horwitz,DA]
通讯作者: Horwitz,DA
DOI: 10.4049/jimmunol.129.6.2519
发表时间: 1982-12
期刊: Journal of immunology
影响因子: 4.4
作者: [K. Nishiya;D. Horwitz]
通讯作者: K. Nishiya;D. Horwitz
Characterization oflymphocytes that suppress IL-2production in systemic lupuserythematosus
系统性红斑狼疮中抑制 IL-2 产生的淋巴细胞的特性
DOI: --
发表时间: 1988
期刊:
影响因子: --
作者: [M. Linker‐Israeli]
通讯作者: M. Linker‐Israeli
12
    Nanoimmunotherapy for chronic immune-mediated diseases
    • 批准号:
      10483819
    • 项目类别:
    • 资助金额:
      $30.0万
    • 财政年份:
      2022
    • 负责人:
      DAVID A HORWITZ
    • 依托单位:
    Flow Cytometry and Immune Monitoring Core
    Flow Cytometer
    CORE--FLOW CYTOMETRY
    海外基金